AVTR
Avantor, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
14.39
▲ 0.13 (0.95%)
MARKET · —
Price
Open
14.25
Prev close
14.25
Day high
14.49
Day low
14.18
Volume
5.22M
Market cap
$9.78B
P/E (TTM)
—
52W range
7.27 – 15.93
Trailing performance
Returnvs SPY
1W
+5.86%
+7.2%
1M
+27.40%
+23.7%
3M
+83.74%
+80.6%
6M
+60.13%
+49.1%
YTD
+26.18%
+13.9%
1Y
+12.27%
-7.7%
3Y
-30.45%
-104.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$9.78B
Enterprise value$13.17B
Revenue (TTM)$6.56B
Gross profit$2.09B
EBITDA$943.70M
Net income$-578.00M
EPS (TTM)$-0.86
Free cash flow$450.34M
Total cash$306.80M
Total debt$3.70B
Book value / share$8.32
Shares outstanding676.36M
Float657.84M
Short % of float9.55%
Dividend yield—
Beta (5Y)0.89
Valuation & profitability ratios
Trailing P/E—
Forward P/E16.40
PEG ratio—
Price / sales—
Price / book1.74
EV / revenue2.01
EV / EBITDA13.96
Gross margin31.82%
Operating margin7.16%
Profit margin-8.81%
Return on equity-9.70%
Return on assets2.69%
Debt / equity65.68
Current ratio1.78
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $6.55B | $6.78B | $6.97B | $7.51B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$530.20M | $711.50M | $321.10M | $662.30M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$530.20M | $711.50M | $321.10M | $662.30M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.19 | 0.21 | +11.1% |
| Mar 2026 | 0.16 | 0.17 | +8.2% |
| Dec 2025 | 0.22 | 0.22 | +1.5% |
| Sep 2025 | 0.23 | 0.22 | -2.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.21 | 16 | $1.64B | +1.1% |
| Next quarter | 0.22 | 15 | $1.68B | +0.9% |
| Current year | 0.81 | 16 | $6.59B | +0.6% |
| Next year | 0.88 | 16 | $6.75B | +2.4% |
Analyst targets & ownership
Mean target$14.56
High target$19.00
Low target$12.00
Implied upside1.25%
Analyst count14
ConsensusNONE
Strong buy / Buy0 / 3
Hold12
Sell / Strong sell0 / 1
Held by insiders1.50%
Held by institutions105.37%
Institutions holding600
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+29.33M
Net buying
Buy transactions
27
75.40M shares
Sell transactions
4
46.06M shares
Net transactions
+31
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
10.14M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 8, 26 | LUCIER GREGORY T Director |
BUY | 10.00K | $83.20K | Indirect |
| May 7, 26 | MEHRA SANJEEV K Director |
STOCK | 25.27K | $0 | Direct |
| May 7, 26 | LUCIER GREGORY T Director |
STOCK | 25.27K | $0 | Direct |
| May 7, 26 | MURTHY MALA Director |
STOCK | 25.27K | $0 | Direct |
| May 7, 26 | MAKIN LOUISE Director |
STOCK | 25.27K | $0 | Direct |
| May 7, 26 | DINGEMANS SIMON Director |
STOCK | 25.27K | $0 | Direct |
| May 7, 26 | SUMME GREGORY L Director |
STOCK | 25.27K | $0 | Direct |
| May 7, 26 | MASSARO JOSEPH R Director |
STOCK | 25.27K | $0 | Direct |
| May 7, 26 | SEVERINO MICHAEL E Director |
STOCK | 25.27K | $0 | Direct |
| May 1, 26 | DINGEMANS SIMON Director |
BUY | 25.00K | $203.50K | Indirect |
| May 1, 26 | BRELLIER LUDOVIC Officer |
STOCK | 146.57K | $0 | Direct |
| Apr 2, 26 | ECK STEVEN W. Officer |
STOCK | 31.64K | $0 | Direct |
| Mar 10, 26 | MEHRA SANJEEV K Director |
BUY | 125.00K | $1.00M | Indirect |
| Feb 19, 26 | LUCIER GREGORY T Director |
BUY | 50.00K | $458.00K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BLENN MARY |
Chief Operating Officer | 253.38K | Stock Award(Grant) |
GOURDIER BENOIT |
Officer | 365.89K | Stock Award(Grant) |
HANKAMER BRITTANY |
Officer | 250.73K | Stock Award(Grant) |
JONES R BRENT |
Chief Financial Officer | 422.59K | Stock Award(Grant) |
LIGNER EMMANUEL |
Chief Executive Officer | 767.14K | Stock Award(Grant) |
MEHRA SANJEEV K |
Director | 508.38K | Stock Award(Grant) |
SOKENU CLAUDIUS O. |
Officer | 254.81K | Stock Award(Grant) |
STUBBLEFIELD MICHAEL |
Chief Executive Officer | 1.92M | Stock Gift |
SUMME GREGORY L |
Director | 483.38K | Stock Award(Grant) |
WALKER COREY |
Officer | 387.55K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
13.84
+3.91% from price
SMA 20
13.61
+6.28% from price
SMA 50
11.61
+24.53% from price
SMA 100
9.96
+44.44% from price
SMA 200
10.21
+41.63% from price
EMA 12
13.75
+4.60% from price
EMA 26
13.03
+10.36% from price
EMA 50
11.99
+19.97% from price
RSI (14)
70.6
Overbought
MACD (12,26,9)
0.72
Hist -0.05
ATR (14)
0.44
3.05% of price
Realised vol 30D
55.8%
Annualised
Bollinger upper
14.82
20, 2σ
Bollinger lower
12.40
20, 2σ
50 / 200 cross
Golden
11.61 vs 10.21
Trend bias
Above 200
+41.63%
Risk profile
Beta vs SPY
0.91
Less volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
55.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-52.5%
Peak to trough
Max drawdown 5Y
-83.2%
Peak to trough
ATR 14
0.44
3.05% of price
Beta (reported)
0.89
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.75
Put-heavy session
Put / call open interest
0.02
Positioning, not flow
Max pain
12.00
-17.0% from spot
ATM implied vol
44.3%
Nearest strike to spot
Skew (10% OTM)
-1.0%
Calls bid over puts
Call volume
170
Contracts, this expiry
Put volume
297
Contracts, this expiry
Heaviest call OI
12.00
50.59K contracts
Heaviest put OI
13.00
992 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Merit Medical Announces Global Operations Leadership Transition
GlobeNewswire · 3d ago
Is Avantor (AVTR) Outperforming Other Medical Stocks This Year?
Zacks · 3d ago
Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down
Zacks · 11d ago
Avantor (AVTR) Q2 2026 Earnings Call Transcript
Motley Fool · 15d ago
BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down
Zacks · 16d ago
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
Zacks · 17d ago
Are Medical Stocks Lagging Avantor (AVTR) This Year?
Zacks · 19d ago
Avantor (AVTR) Is Up 20.5% After Raising 2026 Guidance On Stronger VWR Organic Growth – Has The Bull Case Changed?
Simply Wall St. · 22d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.